Dysregulation of ferroptosis-related plasma biomarkers in treatment-free patients with relapsing-remitting multiple sclerosis in clinical remission: a case-control study.

Authors

Mahdieh Nazari-Robati, Beydolah Shahouzehi, Mahdis Rahimi Naiini

Published in

Acta neurologica Belgica. Aug 03, 2026. Epub Aug 03, 2026.

Abstract

Ferroptosis, an iron-dependent form of programmed cell death characterized by lipid peroxidation, has emerged as a key mechanism associated with neuroinflammation. This process is particularly relevant in relapsing-remitting multiple sclerosis (RRMS), where neuroinflammatory pathways contribute significantly to disease pathology.
This study included 38 patients with RRMS and 38 healthy controls. Plasma levels of key ferroptosis-related biomarkers, including malondialdehyde (MDA), glutathione (GSH), and glutathione peroxidase 4 (GPX4), as well as iron and ferritin, were analyzed.
The analysis demonstrated significantly elevated levels of MDA, iron, and ferritin in the RRMS group compared to the control group with p-values of 0.004, 0.042, and 0.038, respectively. Conversely, GSH and GPX4 levels were significantly reduced in the RRMS group with p-values of 0.028, and 0.014, respectively. A significant correlation was observed between MDA and iron levels in the control group (r = 0.346, p = 0.045).
The significant differences in plasma levels of ferroptosis-related biomarkers between RRMS patients and healthy controls suggest a potential role for ferroptosis in the pathogenesis of multiple sclerosis.

PMID:
42545622
Bibliographic data and abstract were imported from PubMed on 03 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.